The Effect of Metabolic Syndrome and its Individual Components on the Duration of the QTc Interval in Different Gene Carriers of the Nitric Oxide Synthase 1 Adapter Protein Gene in Patients with Schizophrenia

Background: it has now been established that genetic factors play an important role in the pathogenesis of schizophrenia, metabolic syndrome, and cardiovascular diseases. Taking into account the literature data and our own scientific background, the general pattern of the pathogenesis of these disorders may be an imbalance in the work of nitric oxide synthase. The aim was to study the effect of metabolic syndrome and its individual components on the duration of the QTc interval in schizophrenia patients with different variants of NOS1AP gene carriage. Patients and Methods: 168 patients with schizophrenia aged 18–55 years were examined. The components of the metabolic syndrome were determined according to the criteria of the International Diabetes Federation from 2005. At the time of admission to the hospital, a standard 12-lead electrocardiogram recording was performed. The calculation of the QTc interval was carried out using the Bazett formula. The components of the metabolic syndrome were determined by colorimetric enzymatic method. Three single nucleotide polymorphic variants of the NOS1AP gene (rs12029454, rs10494366 and rs12143842) were selected for genotyping. Results: it was found that abdominal obesity had a significant effect on the QTc interval only in the case of carrying the GG rs12029454 genotype. The presence of arterial hypertension increased the duration of the QTc interval in patients with the genotype GG rs12029454, TT rs10494366 and TT rs12143842. It was also found that hypertriglyceridemia is an additional factor affecting the QTc interval in patients carrying the GG rs12029454 genotype. Conclusion: the results of the study confirmed our hypothesis that the nature of the relationship between the duration of the QTc interval and the components of the metabolic syndrome differs among different variants of the NOS1AP gene in patients with schizophrenia.

1. Gao HX, Regier EE, Close KL. International Diabetes Federation World Diabetes Congress 2015. J Diabetes. 2016;8(3):300–302. doi: 10.1111/1753-0407.12377

2. Liang Z, Wang Z, Liu X, He Y. Confronting the global obesity epidemic: investigating the role and under lying mechanisms of vitamin D in metabolic syn drome management. Front Nutr. 2024;11:1416344. doi: 10.3389/fnut.2024.1416344

3. Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, Assi HI. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022;23(2):786. doi: 10.3390/ijms23020786

4. Nikiforova TI, Musaeva OM. The metabolic syndrome as cardiovascular risk factor. Russian Journal of Car diology. 2023;28(5):27–28. (In Russ.).

5. Kar N, Barreto S. Influence of Lifestyle Factors on Metabolic Syndrome in Psychiatric Patients Attend ing a Community Mental Health Setting: A Cross-sec tional Study. Indian J Psychol Med. 2024;46(4):313 322. doi: 10.1177/02537176231219770

6. Kornetova EG, Gerasimova VI, Goncharova AA, Ham ina VV, Mednova IA, Kornetov AN, Ivanova SA. Met abolic syndrome in a population of in-patients with schizophrenia in the Western Siberia. Psychiatry (Moscow) (Psikhiatriya) 2021;19(4):52–60. (In Russ.) doi: 10.30629/2618-6667-2021-19-4-52-60

7. Liu J, Fu L. Metabolic syndrome in patients with schizophrenia: Why should we care. Medicine (Baltimore). 2022;101(32):e29775. doi: 10.1097/MD.0000000000029775

8. Galkin SA, Kornetova EG, Mednova IA, Tiguncev VV, Kornetov AN. Prevalence and Risk Factors for Long QT Interval Syndrome in Patients with Schizophre nia during Antipsychotic Treatment. Current Thera py of Mental Disorders. 2024;(2):32–39. (In Russ.). doi: 10.21265/PSYPH.2024.31.31.004

9. Malin DI, Bulatova DR, SHustova LYU. Long qt syn drome in patients with schizophrenia in a city psychiatric hospital. Social and Clinical Psychiatry. 2024;34(1):19–25. (In Russ.).

10. Ponce-Balbuena D, Deschênes I. Long QT syndrome — Bench to bedside. Heart Rhythm O2. 2021;2(1):89 106. doi: 10.1016/j.hroo.2021.01.006

11. Du W, Ge MW, Hu FH, Jia YJ, Zhao DY, Cheng YJ, Chen HL. QTc prolongation in patients with schizo phrenia taking antipsychotics: Prevalence and risk factors. J Psychopharmacol. 2023;37(10):971–981. doi: 10.1177/02698811231190864

12. Mednova IA, Pozhidaev IV, Tiguntsev VV, Bocharo va AV, Paderina DZ, Boiko AS, Fedorenko OY, Kor netova EG, Bokhan NA, Stepanov VA, Ivanova SA. NOS1AP Gene Variants and Their Role in Metabolic Syndrome: A Study of Patients with Schizophrenia. Biomedicines. 2024;12(3):627. doi: 10.3390/biomedicines12030627

13. Lv H, Li J, Gao K, Zeng L, Xue R, Liu X, Zhou C, Yue W, Yu H. Identification of genetic loci that overlap between schizophrenia and metabolic syndrome. Psychiatry Res. 2022;318:114947. doi: 10.1016/j.psy chres.2022.114947

14. Edwards KL, Wan JY, Hutter CM, Fong PY, Santori co SA. Multivariate linkage scan for metabolic syn drome traits in families with type 2 diabetes. Obesity (Silver Spring). 2011;19(6):1235–1243. doi: 10.1038/oby.2010.299

15. Gough SC, O’Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribu tion? J Psychopharmacol. 2005;19(6 Suppl):47–55. doi: 10.1177/0269881105058380

16. Esen-Sehir D, Kopf J, Hägele S, Plichta MM, Reif A, Freudenberg F. Influence of NOS1AP Risk Variants on the Corrected QT (QTc) Interval in the Pharma cotherapy of Schizophrenia. Pharmacopsychiatry. 2022;55(5):266–273. doi: 10.1055/a-1811-7241

17. Mosolov SN. SHkaly psihometricheskoj ocenki simp tomatiki shizofrenii i koncepciya pozitivnyh i neg ativnyh rasstrojstv. M., 2001:238. (In Russ.). LBC R645.090-3,07

18. Kornetova EG, Galkin SA, Mednova IA, Tsiguntsev VV, Paderina DZ, Ivanova SA. The association of NOS1AP gene polymorphisms with the duration of the QT interval in patients with schizophrenia receiving antipsychotic therapy. S.S. Korsakov Journal of Neu rology and Psychiatry. 2025;125(1):98-104. (In Russ.) doi: 10.17116/jnevro202512501198

19. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome — a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469–480. doi: 10.1111/j.1464 5491.2006.01858.x

20. Bazett HC. An analysis of the time-relations of elec trocardiograms. Heart. 1920;7:353–370. 21. Özsoy F, Zorlu Ç, Kaya Ş. Electrocardiographic Evalu ation of the Ventricular Arrhythmia Risk in Patients Diagnosed With Schizophrenia. Alpha Psychiatry. 2021;22(2):85–89. doi: 10.5455/apd.7015

21. Sun GZ, Zhou Y, Ye N, Wu SJ, Sun YX. Independent Influence of Blood Pressure on QTc Interval: Results from a General Chinese Population. Biomed Res Int. 2019:1656123. doi: 10.1155/2019/1656123

22. Oslopov VN, Afanasyeva TYU, Oslopova YUV. Hyper tension and long QT. Practical Medicine. 2014;(6):18 21. (In Russ.).

23. Lu J, Hu C, Hu W, Zhang R, Wang C, Qin W, Yu W, Xiang K. A common variant of NOS1AP is associated with QT interval duration in a Chinese population with Type 2 diabetes. Diabet Med. 2010;27(9):1074 1079. doi: 10.1111/j.1464-5491.2010.03072.x

24. Lehtinen AB, Newton-Cheh C, Ziegler JT, Langefeld CD, Freedman BI, Daniel KR, Herrington DM, Bowden DW. Association of NOS1AP genetic variants with QT in terval duration in families from the Diabetes Heart Study. Diabetes. 2008;57(4):1108–1114. doi: 10.2337/db07-1365

25. Park B, Lee YJ. Metabolic syndrome and its compo nents as risk factors for prolonged corrected QT in terval in apparently healthy Korean men and women. J Clin Lipidol. 2018;12(5):1298–1304. doi: 10.1016/j.jacl.2018.07.004

26. Faramawi MF, Wildman RP, Gustat J, Rice J, Abdul Kareem MY. The association of the metabolic syn drome with QTc interval in NHANES III. Eur J Epide miol. 2008;23(7):459–465. doi: 10.1007/s10654-008 9252-4

27. Marjamaa A, Newton-Cheh C, Porthan K, Reunanen A, Lahermo P, Väänänen H, Jula A, Karanko H, Swan H, Toivonen L, Nieminen MS, Viitasalo M, Peltonen L, Oikarinen L, Palotie A, Kontula K, Salomaa V. Com mon candidate gene variants are associated with QT interval duration in the general population. J Intern Med. 2009;265(4):448–458. doi: 10.1111/j.13652796.2008.02026.x

28. Shah SA, Herrington DM, Howard TD, Divers J, Ar nett DK, Burke GL, Kao WH, Guo X, Siscovick DS, Chakravarti A, Lima JA, Psaty BM, Tomaselli GF, Rich SS, Bowden DW, Post W. Associations between NOS1AP single nucleotide polymorphisms (SNPs) and QT interval duration in four racial/ethnic groups in the Multi-Ethnic Study of Atherosclerosis (MESA). Ann Noninvasive Electrocardiol. 2013;18(1):29–40. doi: 10.1111/anec.12028

29. Tomás M, Napolitano C, De Giuli L, Bloise R, Subirana I, Malovini A, Bellazzi R, Arking DE, Marban E, Chakra varti A, Spooner PM, Priori SG. Polymorphisms in the NOS1AP gene modulate QT interval duration and risk of arrhythmias in the long QT syndrome. J Am Coll Cardiol. 2010;55(24):2745–2752. doi: 10.1016/j.jacc.2009.12.065

30. Aarnoudse AJ, Newton-Cheh C, de Bakker PI, Straus SM, Kors JA, Hofman A, Uitterlinden AG, Wit teman JC, Stricker BH. Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study. Circulation. 2007;116(1):10–16. doi: 10.1161/CIRCULATIONAHA.106.676783

31. Ronchi C, Bernardi J, Mura M, Stefanello M, Badone B, Rocchetti M, Crotti L, Brink P, Schwartz PJ, Gnecchi M, Zaza A. NOS1AP polymorphisms reduce NOS1 activ ity and interact with prolonged repolarization in arrhythmogenesis. Cardiovasc Res. 2021;117(2):472 483. doi: 10.1093/cvr/cvaa036